ClinicalTrials.gg
RecruitingNCT07207707Updated May 20, 2026

A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies

A Phase 1 interventional study of KQB548 in Solid Tumor Malignancies, sponsored by Kumquat Biosciences Inc.. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Kumquat Biosciences Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
78
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are:

  • What is the safe dose of KQB548?
  • Does KQB548 decrease the size of the tumor?
  • What happens to KQB548 in the body?
02

Conditions studied

  • Solid Tumor Malignancies

Keywords

  • KRAS
  • G12D
03

In context

Lead sponsor

Kumquat Biosciences Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, locally advanced or PDAC, CRC, or NSCLC with a KRAS G12D mutation
  • Progressed on, or intolerant to at least one prior line of systemic standard of care therapy
  • according to v1.1
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a KRAS G12D inhibitor or pan-RAS inhibitor
  • History of intestinal disease, uncontrolled inflammatory bowel disease (e.g., Crohn's disease, Ulcerative Colitis), major esophageal or gastric surgery, or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study intervention or result in inability to swallow oral medications
  • Poorly controlled ascites and/or pleural effusion
  • Requires treatment with a strong and/or moderate inhibitor or inducer
  • Requires treatment with a proton-pump inhibitor
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    Monotherapy Dose Escalation

    Drug: KQB548

Interventions

  • DrugKQB548

    Oral KQB548

06

What researchers measure

Primary outcomes

  1. Safety,Tolerability, MTD/MAD and/or RDE in the Study Population

    Safety characterized by type, incidence and severity of treatment emergent adverse events (TEAEs), SAEs, and DLTs

    Time frame: Up to 30 months

Secondary outcomes

  1. Plasma Concentration-time curve (AUC)

    Time frame: Up to 30 months

  2. Maximum plasma concentration (Cmax)

    Time frame: Up to 30 months

  3. Time to maximum plasma concentration (tmax)

    Time frame: Up to 30 months

  4. Overall Response Rate (ORR)

    Per RECIST v1.1

    Time frame: Up to 30 months

  5. Duration of Response (DOR)

    Per RECIST v1.1

    Time frame: Up to 30 months

  6. Time to Response (TTR)

    Per RECIST v1.1

    Time frame: Up to 30 months

  7. Disease Control Rate (DCR)

    Per RECIST v1.1

    Time frame: Up to 30 months

  8. Progression Free Survival (PFS)

    Per RECIST 1.1

    Time frame: Up to 30 months

  9. Overall Survival (OS)

    Per RECIST v1.1

    Time frame: Up to 30 months

  10. Peak Plasma Concentration (Cmax) in Fed and Fasted States for Food Effect

    Time frame: Up to 30 months

  11. Concentration Time Curve (AUC) in Fed and Fasted States for Food Effect

    Time frame: Up to 30 months

  12. Time to maximum plasma concentration (tmax) in Fed and Fasted States for Food Effect

    Time frame: Up to 30 months

  13. Evaluate Changes in QTc (mSec)

    Time frame: Up to 30 months

07

Study locations

13 of 13 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Oct 6, 2025
StartActual
Sep 16, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Mar 2027
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07207707
Lead sponsor
Kumquat Biosciences Inc.
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Sep 16, 2025
Primary completion
Sep 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
May 20, 2026

Study contacts

Kumquat Clinical Development
Contact
kumquatstudies@kumquatbio.com
858-214-2700

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion